Physician profile
Kenneth Nickle
NPI 1790849081
$6,923.07
in general payments reported to CMS, 2019-2025
40 companies · $1,451 in 2025
The $1,451 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $987 · 2020: $518 · 2021: $871 · 2022: $738 · 2023: $1,142 · 2024: $1,216 · 2025: $1,451.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,809.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,809.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,239.71 | 2021-2025 | |
| Novo Nordisk INC | $772.75 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $564.02 | 2019-2023 | Jardiance |
| Pfizer INC. | $562.52 | 2019-2025 | |
| Otsuka America Pharmaceutical, INC. | $556.23 | 2022-2025 | Rexulti |
| Lilly USA, LLC | $318.33 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Allergan, INC. | $287.89 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $269.65 | 2019-2024 | Trintellix |
| Astrazeneca Pharmaceuticals Lp | $263.45 | 2019-2025 | Airsupra, Farxiga |
| Lundbeck LLC | $196.07 | 2025 | Rexulti |
| Amgen INC. | $180.66 | 2019-2025 | Repatha, Evenity |
| Dexcom, INC. | $158.74 | 2021-2025 | Dexcom G6 Transmitter |
| Janssen Pharmaceuticals, INC | $137.82 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $115.48 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $115.40 | 2019-2023 |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $114.51 | 2019-2024 | Shingrix, Trelegy Ellipta, Arexvy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $107.71 | 2023-2025 | Xifaxan, Trulance |
| Axsome Therapeutics, INC. | $94.35 | 2022-2025 | Auvelity |
| Astellas Pharma US INC | $86.80 | 2019-2023 | Veozah |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $81.23 | 2024-2025 | Caplyta |
| Merck Sharp & Dohme LLC | $72.71 | 2019-2024 | Verquvo, Gardasil 9, Gardasil |
| Exact Sciences Corporation | $68.70 | 2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Xeris Pharmaceuticals, INC. | $57.23 | 2023-2025 | Gvoke Hypopen |
| Vanda Pharmaceuticals INC. | $56.86 | 2025 | Fanapt, Hetlioz |
| Philips North America LLC | $55.37 | 2019 | |
| Amarin Pharma, INC. | $52.32 | 2019-2021 | |
| Phathom Pharmaceuticals, INC. | $46.63 | 2024-2025 | Voquezna |
| Boston Scientific Corporation | $39.50 | 2024-2025 | General - Erectile Dysfunction |
| Ucb, INC. | $35.48 | 2024 | Briviact |
| Ardelyx, INC. | $35.00 | 2025 | Ibsrela |
| Corcept Therapeutics | $27.31 | 2020 | |
| Optinose US, INC. | $21.78 | 2025 | |
| Organon LLC | $21.03 | 2023 | Nexplanon |
| Neurocrine Biosciences, INC. | $19.86 | 2025 | |
| Biohaven Pharmaceuticals, INC. | $18.77 | 2021 | |
| Hologic Sales and Service, LLC | $16.32 | 2025 | Aptima, Thinprep 2000 Processor |
| E.R. Squibb & Sons, L.L.C. | $15.55 | 2021 | |
| Dynavax Technologies Corporation | $15.42 | 2025 | Heplisav-B |
| Eisai INC. | $12.44 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $11.47 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Nickle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.